1st-line treatment of postmenopausal women w/ hormone receptor +ve or hormone receptor unknown locally advanced or metastatic breast cancer. Advanced breast cancer in postmenopausal women w/ disease progression following antiestrogen therapy. Adjuvant treatment of postmenopausal women w/ hormone receptor +ve early breast cancer. Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 yr of adjuvant tamoxifen therapy.
May decrease bone mineral density. Monitor serum cholesterol. Moderate decreases in lymphocyte counts. Increased SGOT, SGPT & γ-GT ≤5x ULN & bilirubin 1.5x ULN. Possible fatigue, dizziness & somnolence; minor influence on ability to drive & use machines. Severe hepatic impairment. Pregnancy & lactation. Childn.
Sign Out
